Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations
Rachael Brake on Unmet Needs with EGFR Exon 20 Insertion-Mutant NSCLC #AACR2020 @rachael_brake @TakedaOncology
